FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function-Reference-Cited by-同舟云学术

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function

Published:2005-01 Issue:1 Volume:11 Page:23-34
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Chen Wei,Chan Anissa S.H.,Dawson Amanda J.,Liang Xueqing,Blazar Bruce R.,Miller Jeffrey S.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference38 articles.

1. Immunobiology of dendritic cells;Banchereau;Annu Rev Immunol.,2000

2. Dendritic cells directly trigger NK cell functions;Fernandez;Nat Med.,1999

3. Natural killer cells and dendritic cells;Moretta;Nat Rev Immunol.,2002

4. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity;Liu;Cell,2001

5. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens;Kadowaki;J Exp Med.,2001

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-classical HLA-E restricted CMV 15-mer peptides are recognized by adaptive NK cells and induce memory responses;Frontiers in Immunology;2023-09-21

2. Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression;Cell Communication and Signaling;2021-05-06

3. Delivery routes matter: Safety and efficacy of intratumoral immunotherapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2021-04

4. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets;Nature Cancer;2020-11-16

5. Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials;Blood Advances;2019-12-09